THE adoption of a new steatotic liver disease resolution by the World Health Assembly has brought liver health into the global noncommunicable disease (NCD) agenda for the first time, marking a historic policy milestone.
Approved by the 79th World Health Assembly on the 21 May 2026, the resolution recognises steatotic liver disease as a key component of the global NCD response. Steatotic liver disease is an umbrella term that includes metabolic dysfunction-associated steatotic liver disease, alcohol-related liver disease and metabolic dysfunction and alcohol-related liver disease.
According to a press release by the European Association for the Study of the Liver (EASL), an estimated 1.5 billion adults globally are living with steatotic liver disease, despite the condition historically receiving little attention in national health plans, global financing frameworks, or accountability mechanisms.
Why the Steatotic Liver Disease Resolution Matters
The resolution comes amid growing concern about the burden of liver disease and its links with other metabolic conditions.
EASL noted that the measure reflects a broader shift away from treating obesity, diabetes, cardiovascular disease and liver disease as separate conditions, instead promoting integrated approaches that address shared risk factors and support coordinated care throughout life.
Data from the EASL-Lancet Commission 2.0 estimated that liver disease contributes to 780 preventable deaths each day across Europe and generates annual economic costs of €55 billion.
The figures underscore why formal recognition is viewed as a prerequisite for political commitment and funding.
Turning Recognition into Action
The measures also emphasise addressing the social and commercial determinants that contribute to liver disease alongside clinical interventions.
A high-level side event held in Geneva shortly after the resolution’s adoption brought experts together to discuss implementation. Conversation focused on translating the policy milestone into practical changes in health systems, including enhanced monitoring, financing reforms and equitable access to prevention and care.
While the resolution represents a significant policy development, EASL stressed that its impact will depend on implementation. The organisation has called on WHO Member States to prioritise national adoption, updating of monitoring frameworks to include liver health indicators, and integrate liver health into NCD plans by the end of 2026, and support the inclusion of liver health indicators within existing WHO monitoring and accountability frameworks to move towards prevention-focused, integrated care models.
For healthcare professionals, the resolution signals growing international recognition of liver disease as a major component of metabolic health and a target for coordinated prevention and long-term care strategies.
